Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV vaccine immunogenicity in female special risk groups
ACTRN12609000571279Phase 3Completed
- Sponsor
- National Health and Medical Research Council
- Start
- Mar 2008
- Countries
- 1
01
Overview
Phase 3, open-label trial of quadrivalent human papillomavirus vaccine in human papillomavirus infection (2 arms), sponsored by National Health and Medical Research Council. Primary endpoint: HPV vaccine immunogenicity. Started Mar 2008; status: completed.
02
Drugs
quadrivalent human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ACTRN12609000571279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000571279.